Dr. Belknap is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
777 Bannock St
# MC7782
Denver, CO 80204Phone+1 303-436-7240
Summary
- Dr. Robert Belknap is an infectious disease specialist in Denver, CO and is affiliated with Denver Health. He received his medical degree from The Ohio State University College of Medicine and has been in practice 19 years. He is experienced in tuberculosis, hiv/aids, and hep c.
Education & Training
University of ColoradoFellowship, Infectious Disease, 2002 - 2005- University of ColoradoResidency, Internal Medicine, 1998 - 2001
Ohio State University College of MedicineClass of 1998
Certifications & Licensure
CO State Medical License 2001 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT Start of enrollment: 2012 Sep 01
- Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis Start of enrollment: 2012 Oct 01
Publications & Presentations
PubMed
- 95 citationsSelf-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis InfectionRobert Belknap, David P. Holland, Pei Jean Feng, Joan Pau Millet, Joan A. Caylà
Annals of Internal Medicine. 2017-11-21 - 35 citationsExposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.Ruth N. Moro, Nigel A. Scott, Andrew Vernon, Naomi K. Tepper, Stefan V. Goldberg
Annals of the American Thoracic Society. 2018-05-01 - 57 citationsAnalysis of Antibody Responses to Mycobacterium leprae Phenolic Glycolipid I, Lipoarabinomannan, and Recombinant Proteins To Define Disease Subtype-Specific Antigenic ...John S. Spencer, Hee Jin Kim, William H. Wheat, Delphi Chatterjee, Marivic Balagon
Clinical and Vaccine Immunology. 2011-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
